Klaviyo (NYSE: KVYO) CEO Bialecki sells 140,646 shares under 10b5-1
Rhea-AI Filing Summary
Klaviyo Co-Chief Executive Officer Andrew Bialecki reported a planned share conversion and sale of common stock. On January 13, 2026, he converted 140,646 shares of Series B Common Stock into the same number of Series A Common Stock, then sold those 140,646 Series A shares in two transactions pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. The weighted average prices were $27.62 per share for 50,319 shares and $27.29 per share for 90,327 shares, leaving him with no directly held Series A shares and 69,274,090 shares of Series B Common Stock reported as directly owned.
The filing also notes that Bialecki is a director, 10% owner, and Co-Chief Executive Officer, and that Series B shares are convertible one-for-one into Series A with no expiration date. He additionally reports indirect interests through several 2023 trusts and shares held by his spouse, while expressly disclaiming beneficial ownership of those indirect holdings except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Common Stock | 140,646 | $0.00 | -- |
| Conversion | Series A Common Stock | 140,646 | $0.00 | -- |
| Sale | Series A Common Stock | 50,319 | $27.62 | $1.39M |
| Sale | Series A Common Stock | 90,327 | $27.29 | $2.47M |
| holding | Series B Common Stock | -- | -- | -- |
| holding | Series B Common Stock | -- | -- | -- |
| holding | Series B Common Stock | -- | -- | -- |
| holding | Series B Common Stock | -- | -- | -- |
Footnotes (1)
- These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Each share of the Issuer's Series B Common Stock, par value $0.001 per share ("Series B Common Stock"), is convertible at any time at the option of the holder into one share of the Issuer's Series A Common Stock, par value $0.001 per share ("Series A Common Stock"), and will automatically convert into one share of Series A Common Stock upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation. The Series B Common Stock has no expiration date. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.425 to $28.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.10 to $27.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Shares held by the Andrew P. Bialecki Grantor Retained Annuity Trust I of 2023, of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Shares held by the Elizabeth L. Bialecki Irrevocable GST Trust of 2023, of which the Reporting Person serves as a trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Shares held by the Andrew P. Bialecki Irrevocable GST Trust of 2023, of which the Reporting Person's spouse serves as a trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
FAQ
What insider transaction did Klaviyo (KVYO) Co-CEO Andrew Bialecki report?
Andrew Bialecki reported converting 140,646 shares of Series B Common Stock into Series A Common Stock on January 13, 2026, and selling all 140,646 Series A shares in two transactions on the same date.
Was Andrew Bialecki’s Klaviyo (KVYO) stock sale under a Rule 10b5-1 plan?
Yes. A footnote states that these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Andrew Bialecki on May 20, 2025.
What is the relationship between Klaviyo’s Series B and Series A Common Stock?
The filing states that each share of Series B Common Stock is convertible at any time at the holder’s option into one share of Series A Common Stock and will automatically convert upon certain events described in the company’s certificate of incorporation. Series B has no expiration date.